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Asthma rehabilitation at high vs. low
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Ulan Sheraliev3, Bermet Estebesova3, Berik Emilov3, Talant Sooronbaev3, Konrad E. Bloch1 and Silvia Ulrich1*
Abstract
Background: To investigate the effect of asthma rehabilitation at high altitude (3100 m, HA) compared to low
altitude (760 m, LA).
Methods: For this randomized parallel-group trial insufficiently controlled asthmatics (Asthma Control Questionnaire
(ACQ) > 0.75) were randomly assigned to 3-week in-hospital rehabilitation comprising education, physical-&breathing-
exercises at LA or HA. Co-primary outcomes assessed at 760m were between group changes in peak expiratory flow
(PEF)-variability, and ACQ) from baseline to end-rehabilitation and 3months thereafter.
Results: 50 asthmatics were randomized [median (quartiles) LA: ACQ 2.7(1.7;3.2), PEF-variability 19%(14;33); HA: ACQ
2.0(1.6;3.0), PEF-variability 17%(12;32)].
The LA-group improved PEF-variability by median(95%CI) -7%(− 14 to 0, p = 0.033), ACQ − 1.4(− 2.2 to − 0.9, p < 0.001),
and after 3 months by − 3%(− 18 to 2, p = 0.103) and − 0.9(− 1.3 to − 0.3, p = 0.002). The HA-group improved PEF-
variability by − 10%(− 21 to − 3, p = 0.004), ACQ − 1.1(− 1.3 to − 0.7, p < 0.001), and after 3 months by − 9%(− 10 to − 3,
p = 0.003) and − 0.2(− 0.9 to 0.4, p = 0.177). The additive effect of HA vs. LA directly after the rehabilitation on PEF-
variability was − 6%(− 14 to 2), on ACQ 0.3(− 0.4 to 1.1) and after 3 months − 5%(− 14 to 5) respectively 0.4(− 0.4 to 1.1),
all p = NS.
Conclusion: Asthma rehabilitation is highly effective in improving asthma control in terms of PEF-variability and
symptoms, both at LA and HA similarly.
Trial registration: Clinicaltrials.gov: NCT02741583, Registered April 18, 2016.
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Background
Asthma is a major global health problem affecting over
300 million people worldwide with increasing prevalence
in developing countries [1]. Asthma causes respiratory
symptoms (mainly cough, dyspnea), limitation of activity
and exacerbations that may require emergency
treatment [1].
The current Global Initiative for Asthma (GINA) has
outlined that patients with asthma should be managed,
according to their level of asthma control, which in-
cludes symptoms during the day, symptoms during the
night, use of reliever medication, limitation of daily ac-
tivity, pulmonary function and exacerbations [1].
Many patients with asthma can be adequately con-
trolled with bronchodilators in combination with inhaled
corticosteroids. However, some asthma patient suffer
from refractory disease despite medical therapy [2] and
even controlled patients have to be prepared for flare-
ups. Besides the pharmacological treatment, rehabilita-
tion programs might be beneficial for asthma patients.
The GINA guidelines state to advice all patients with
chronic airflow disease for rehabilitation, whereas high
altitude treatment has evidence level C [1].
Rehabilitation contains not only physical training and
breathing exercises but also education, including smok-
ing cessation [3, 4] aiming to deliver a profound insight
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into the disease and the ability to adequately react on
exacerbations [5].
For decades, asthma patients have been sent to altitude
clinics aiming to improve asthma control [6, 7]. At high
altitude there is less allergen exposure [8, 9], e.g. house dust
mites do not exist > 1600m above sea level (asl). A factor
that might also mitigate a potential beneficial effect of alti-
tude exposure on asthma control is the dry and generally
less polluted air resulting in less inflammation [10, 11] and
improved respiratory function [12]. In addition, the de-
creased air density at altitude leads to reduced airway resist-
ance [13], which might additionally help to increase exercise
capacity for asthmatics at altitude. The mountain environ-
ment may also signify less psychosocial stress for many
patients having the opportunity to leave their everyday
environment behind and enjoy a pleasant stay at altitude.
Stress is associated with reduced sensitivity to endogenous
glucocorticosteroids and chronic psychological stress has
been associated with asthma exacerbation, whereas stress
reduction seems to improve asthma control [14, 15].
Kyrgyzstan is a lower middle- income country with
less access to advanced drug therapies [16]. Thus, aller-
gen avoidance along with an intense asthma education
and rehabilitation program is potentially of even greater
importance in order to avoid disease exacerbations or
chronification due to low asthma control.
As in the Swiss Alps, since many years asthma patients
have been taken to Tuja Ashu, a high-altitude clinic located
at 3100m asl in the mountain area of the Kyrgyz Republic
to improve asthma control. However, randomized con-
trolled trials, which compare the effect of asthma rehabilita-
tion at high compared to low altitude are completely
lacking. Whether the reported positive effect of asthma re-
habilitation at Alpine resorts is due to hypobaric hypoxic
environment at altitude with less allergen exposure or due
to the comprehensive rehabilitation program, including pa-
tient education and exercise or both is not clear to date.
We aimed to study a specific in-patient asthma re-
habilitation program and its effectiveness on asthma
control and investigated the effects of performing the re-
habilitation at the Tuja Ashu high altitude clinic (HA),
3100 m, in comparison to the same program performed
at low altitude in Bishkek (LA), 760 m. We hypothesized
that a 3-week rehabilitation at high altitude improves
PEF-variability and ACQ compared to a low altitude 3-
week rehabilitation. Additionally, we hypothesized the
effects would be sustained at 3 months follow-up.
Material and methods
Design
In this randomized parallel-group trial asthmatics were
assigned to in-patient rehabilitation either at LA (Bishkek,
Kyrgyzstan, 760m) or HA (Tuja Ashu, Kyrgyzstan, 3100
m), between May and October 2016. The study was
approved by the local Kyrgyz Ethics Committee (01–8/
151) and the Ethics Committee Zurich (2016–00076).
Participants
Adults (≥18 years) diagnosed with atopic (positive prick
test) or non-atopic asthma according to the GINA-
guidelines were eligible if there disease was not well con-
trolled, defined as asthma control questionnaire (ACQ)
score > 0.75 [17] and that have given written informed
consent. Patients living permanently at > 1′000 m asl,
heavy smokers (≥20 cigarettes/day), patients with a his-
tory of acute mountain sickness (AMS) at altitudes < 3′
100 m, or with serious concomitant diseases (Additional
file 1) were excluded. Study physicians recruited patients
in the National Center for Cardiology and Internal
Medicine in Bishkek (Kyrgyzstan).
Intervention
The 3-week rehabilitation program (for detailed descrip-
tion see Additional file 1) was identical for both groups
and consisted of patient education, endurance training,
muscle strength training, breathing exercises and guided
walks (each 5x/week for 30-45 min and a total duration
of 5 h/day). All patients received an asthma action plan
containing instructions on recognition of worsening
asthma control and on suggested actions [1]. Patients
from the HA group were transferred via minibus, to the
high altitude clinic and back to Bishkek, respectively.
Outcomes
All outcomes were assessed at 760 m asl.
The co-primary outcomes were the differences of the
changes between the two groups (LA vs. HA) in the
score of the ACQ and the PEF-variability from baseline
to the end of the 3-week rehabilitation and to 3-month
follow-up (FU). The PEF-variability was computed as
[(day’s highest-day’s lowest)/mean of day’s highest+low-
est] [1]. PEF measures were made four times daily.
Secondary outcomes were the percentage of patients
with well controlled or partially controlled asthma (ACQ
score < 1.5), the between-group differences of the change
in the following assessments to end of rehabilitation and
FU: forced expiratory volume in 1 s (FEV1), PEF-variability,
asthma-related quality of life (AQLQ), generic quality of
life assessed by the short-form 36 questionnaire (SF-36),
exercise performance assessed by the sit-to-stand (STS), 6
min walking distance (6MWD), airway inflammation
assessed by the exhaled nitric oxide (FeNO) [18] and blood
eosinophils and hemoglobin concentration.
The HA-group additionally filled out the Environmental
Symptom Questionnaire cerebral score (AMS-c) at the
second day at altitude to assess safety of altitude exposure
symptoms of acute mountain sickness [19].
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Sample size estimation
With an estimated standard deviation of the ACQ-score
of 1 [7] and a minimal clinical important difference of
0.5 [20], 16 patients needed to be included per group to
achieve a power of 0.8 with an alpha of 0.05. For the
same power of the co-primary endpoint PEF-variability,
we assumed a difference of 3% in PEF-variability with a
standard deviation of 3% between the groups again indi-
cating 16 patients. Thus, to account for drop-outs, we
aimed to include at least 20 patients per group.
A list of the eligible patients was sent to an independ-
ent coordinator who randomly allocated patients to re-
habilitation at LA or HA by a computer program (Stata
14.0, StataCorp, College Station, Texas, USA) with the
plugin “rct_minim”) providing minimisation with regard
to atopy [21]. Blinding of the intervention (rehabilitation
and altitude) was intrinsically not possible.
Data analysis
The analysis was performed on data from all participants
undergoing rehabilitation at one of the two locations. Data
are summarized as median (interquartile range, IQR). The
primary and secondary outcomes were evaluated with the
Wilcoxon test for paired samples within group and the
Mann-Whitney-U-Test for the difference between groups.
Difference between the change in PEF-variability and
change in ACQ from baseline to 3 weeks and from base-
line to 3months follow-up were calculated and presented
as median differences with 95% confidence intervals. A
p < 0.05 was considered statistically significant.
Linear regression analysis was used to estimate the ef-
fect of the patients’ characteristics on the change of the
PEF-variability. Statistical analyses were conducted with
SPSS 22 (SPSS, Chicago, Illinois, USA).
Data reporting
The data is reported in adherence with the CONSORT
guidelines.
Results
Of 159 eligible patients 50 were included in the study: 25
per group with one patient in each group not receiving the
intervention (one for professional and one family reasons),
see study flow chart Fig. 1. Therefore, the analysis was per-
formed per protocol on data from all participants under-
going rehabilitation. Baseline characteristics are shown in
Table 1.
Primary outcomes
At baseline, the elevated values of ACQ and PEF-variability
confirmed that the asthma was poorly controlled according
to selection criteria. Both outcomes significantly improved
during the 3-week rehabilitation program at LA although
PEF-variability was reduced to below 10% in the HA-group
only. After 3months, the improvements in ACQ were
maintained in both groups while PEF-variability remained
significantly below baseline and below 10% in the HA-
Fig. 1 Study flow chart
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group only. Moreover, the absolute values of PEF-
variability at 3 weeks and 3months were lower in the HA-
group compared to the LA-group. There was no significant
difference between groups (HA vs. LA) with regard to the
changes of the ACQ and the PEF-variability from baseline
to end of rehabilitation at 3 weeks and FU at 3months
(Table 2 and Figs. 2, 3).
Secondary outcomes
The percentage of patients with well controlled or partly
controlled asthma (ACQ < 1.5) [17] increased in the LA-
group from 20, to 83% (p < 0.001) after the rehabilitation
and to 54% (p = 0.003) at 3months; corresponding values
in the HA-group were 16, 71% (p < 0.001) and 48% (p =
0.008) respectively).
At the end of the 3-week rehabilitation almost all sec-
ondary outcomes, including the 6MWD, STS, lung func-
tion and quality of life assessed at 760m significantly
improved in both groups (Tables 3 and 4). Asthma con-
trol measured by the use of reliever medication (ACQ
question number 6) significantly improved with rehabili-
tation (LA p = 0.025, HA p = 0.002) and to a similar ex-
tent in both groups (Additional file 1: Table S1).
We found that the sit-to-stand test and the FeNO im-
proved significantly more in the HA-group compared to
the LA-group. Median changes of other secondary
outcomes assessed before and after the 3-week rehabilita-
tion at 760m were similar at LA or HA (Table 3). Im-
provements of secondary outcomes were mostly
maintained at the follow-up assessment at 3months. The
changed of the STS remained higher in the HA compared
to LA.
Furthermore, the HA-group significantly increased the
hemoglobin concentration compared to the LA-group
from baseline to week 3 [median difference 7 (4 to 11)
g/L, p > 0.001].
Linear regression analysis (Table 5) revealed that the
PEF-variability before the rehabilitation program and the
rehabilitation at HA vs. LA were independent predictors
of the improvement in PEF-variability [ΔPEF-variability
(baseline-end rehabilitation) = − 0.375 + 0.914(baseline
PEF-variability) + 0.091(Group); R2 0.666, p < 0.001].
Adverse events and safety measures
Of the 25 patients undergoing rehabilitation at HA,
symptoms of AMS defined as score ≥ 0.7 were present in
11 patients in Bishkek (760 m) and 6 patients at altitude
with only two having a higher score at HA. One patient
needed medical treatment for an AMS with severe head-
ache and a very high AMS score of 4.46.
During the rehabilitation program the following events
occurred, which were not directly linked to the training:
Table 1 Baseline characteristics
Low altitude (760 m) rehabilitation group High altitude (3100m) rehabilitation group
Number of participants (Females) 25 (18, 72%) 25 (16, 64%)
Age, years 47 (34;53) 43 (33;49)
Body mass index, kg/m2 24 (23;27) 26 (23;29)
Non-smokers, n (%) 25 (100) 25 (100)
Atopy, n (%) 23 (92) 23 (92)
Peak expiratory flow, L/min 311 (274;378) 326 (261;368)
FeNO, ppb 37 (26;46) 51 (37;73)
Note: Data are given as median (quartiles) or numbers (%)
Abbreviations: FeNO exhaled nitric oxid
Table 2 Primary endpoints assessed at low altitude (760 m)
Low altitude rehabilitation group High altitude rehabilitation group Between group
difference of
changes from
BL to 3 weeks
Between group
difference of
changes from
BL to 3 months
Baseline End of rehabilitation
(3 weeks)
Follow-up
(3 months)
Baseline End of rehabilitation
(3 weeks)
Follow-up
(3 months)
PEF-Var. 19 (14;33) 15 (8;23) 15 (9;24) 17 (12;32) 6 (4;9)# 8 (5;14)#
change −7.4 (−13.9
to 0)*
−2.5 (-17.5
to 2.1)
−10.4 (−21.3
to −3.4)**
−8.9 (-10.3
to -2.8)**
− 5.8 (− 14
to 2)
− 5 (− 13.6
to 5.0)
ACQ 2.7
(1.7;3.2)
0.8 (0.4;1.6) 1.4 (0.9;2.1) 2.0
(1.6;3.0)
0.9 (0.4;1.6) 1.6 (0.9;3.0)
change -1.4 (-2.2
to −0.9)***
− 0.9 (− 1.3
to −0.3)**
−1.1 (−1.3
to − 0.7)***
−0.2 (-0.9
to 0.4)
0.3 (-0.4
to 1.1)
0.4 (− 0.4
to 1.1)
Note: Data are given as median (quartiles) and median difference (confidence interval)
Abbreviations: PEF-Var. Peak-flow variability, %, ACQ Asthma Control questionnaire. *: p < 0.05; **: p < 0.01; ***: p < 0.001 tested with Wilcoxon test for paired
samples (baseline vs. 3 weeks follow up and baseline vs. 3 months follow up). #: p < 0.05 vs. low altitude group
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In the LA rehabilitation group, one patient had a slight
cold, one had temporary fever and one had a sore throat;
in the HA one patient was treated with acetazolamide for
1 day for relevant AMS (including headache), one had
slight headache, one had intermittent diarrhea and one
had an asthma exacerbation defined as a decline in PEF of
> 12%. None of the patient had to interrupt the whole
rehabilitation program for > 1 day due to symptoms.
Discussion
This is the first randomized controlled trial which inves-
tigated the additional effect of undergoing a 3-week
rehabilitation program at HA (3100 m) vs. LA (760 m)
on asthma control in patients with uncontrolled asthma.
We found that a comprehensive 3-week rehabilitation
program including education, endurance training,
muscle- and breathing exercise significantly improved
asthma control both at low and high altitude. The effect
of the rehabilitation at HA was not superior compared
to the same rehabilitation program at LA in ameliorating
asthma control as assessed by the ACQ and PEF-
variability. Nevertheless, rehabilitation at HA was well
tolerated and led to a better improvement of exercise
capacity (STS) and airway inflammation assessed by
FeNO. In addition, regression analysis revealed that the
overall improvement in PEF-variability from baseline to
3 weeks was better in the HA vs. LA-group when con-
trolling for relevant confounders such as age, gender
and the baseline absolute PEF. Thus suggesting that pa-
tients with a higher baseline PEF-variability may benefit
more from a rehabilitation at altitude.
For many years, asthma patients are taken to HA in
order to improve their asthma control in a presumptively
cleaner environment with less allergen exposure. The ef-
fect of training at altitude (1600m asl) on asthma control
was investigated in a prospective, uncontrolled study by
Rijssenbeek-Nouwens and coworkers [7], which showed
that sensitized and unsensitized patients improved their
ACQ score by 1.4 and 1.5 after 12 weeks. However, as this
study was lacking a low-altitude control group, it remains
unclear whether the favorable effect was due to altitude
exposure or the educational and exercise training per se.
In the present randomized trial, we could not show an
additive effect of providing the rehabilitation at HA vs.
LA on our primary outcome. This extends data from a
previous non-randomized study suggesting that that al-
lergen avoidance during HA sojourns improved bron-
chial hyperresponsiveness in adolescents with severe
Fig. 2 Peak flow variability of both groups, median changes (95%CI) from baseline to end rehabilitation after 3 weeks and 3months follow up
and median differences (95%CI) between groups
Fig. 3 Asthma control of both groups, median changes (95%CI) from baseline to end rehabilitation after 3 weeks and 3 months follow up and
median differences (95%CI) between groups
Saxer et al. BMC Pulmonary Medicine          (2019) 19:134 Page 5 of 8
asthma [6]. Additional benefits of HA than mere aller-
gen reduction have been postulated such as dryer, thin-
ner and cleaner air, less fungi and an increased vitamin-
D production due to increased exposure to sunlight [8].
In our study, the vast majority of participants (92%)
had atopic asthma, but the improvements found with
the rehabilitation at HA were similar as with the same
program performed at LA. Nevertheless, we found a sig-
nificantly greater reduction of FeNO in patients under-
going HA- vs. LA rehabilitation. This may point towards
less airway inflammation in the HA-group. The findings
are especially remarkable as FeNO measurements were
performed at 760 m on the day after return from HA
presumably when patients were already re-exposed to
some allergens and other noxious stimuli. Our data are
in line with previous reports of beneficial effects of HA
rehabilitation in adults and children on FeNO and
asthma control in both, allergic and non-allergic asth-
matics according to nonrandomized studies [7, 11, 22].
Several randomized trials showed a positive impact of
physical exercise and training on asthma control [5, 23–25]
and maximal performance but no improvements in lung
function [26]. Our study confirmed that a 3-week compre-
hensive rehabilitation program at both low and high
Table 3 Secondary endpoints
Low altitude High altitude Between group
difference of
changes from
BL to 3 weeks
Between group
difference of
changes from
BL to 3 months
Baseline End of
rehabilitation
(3 weeks)
Follow-up
(3 months)
Baseline End of
rehabilitation
(3 weeks)
Follow-up
(3 months)
FEV1, %pred. 61 (42;77) 96 (54;80)* 71 (58;83)* 64 (59;71) 78 (67;83)*** 72 (58;85)* 3.6 (−4.9 to
10.9)
1.7 (-7.3 to 9.6)
FVC, %pred. 83 (63;93) 87 (79;96)* 87 (77;94) 82 (74;92) 91 (83;98)** 84 (78;95) 1.5 (−5.5 to
10.2)
−.45 (-7.0 to 6.1)
FEV1/ FVC, pre .63 (.52;.69) .63 (.53;.70) .67 (.54;.70)* .67 (.59;.71) .70 (.63;.75)*** .69 (.6;.75)** .01 (−.03 to .05) .01 (−.04 to .06)
6MWD, m 490 (452;
510)
521 (493;
549)***
504 (486;
536)*
536 (491;
571)
571 (522;624)** 570 (517;
607)
−2 (-24 to 22) 4 (-26 to 31)
STS, repetitions 21 (19;24) 24 (21;26)** 25 (22;28)** 25 (23;28) 36 (30;40)*** 30 (27;39)*** 7 (4 to 11) 4 (0 to 7)
FeNO, ppb 37 (25;58) 19 (36;51) – 51 (35;76) 27 (23;52)** – −18 (−36 to 0)
Hemoglobin,
g/l
139 (131;
150)
139 (125;145) 142 (127;
158)
145 (138;166) 7 (4 to 11)
EOS, 10^9/l .39 (.28;.63) .31 (.18;.57) .38 (.28;.57) .26 (.18;.45) −.05 (−.16 to
.04)
EOS, % 6.3 (5.0;9.3) 5.4 (2.7;7.1)* – 6.2 (5.1;8.6) 3.9 (2.4;6.5)*** – −1.1 (−2.6 to
0.5)
Note: Data are given as median (quartiles) and median difference (confidence interval)
Abbreviations: FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, 6MWD 6min walking distance, STS Sit-to-stand, FeNO exhaled nitric oxid, EOS
blood eosinophils
*: p < 0.05; **: p < 0.01; ***: p < 0.001 tested with Wilcoxon test for paired samples (baseline vs. 3 week follow up and baseline vs. 3 months follow up); bold:
significant between group differences
Table 4 Effect of HA and LA rehabilitation on Quality of Life
Low altitude High altitude
Baseline End of
rehabilitation
(3 weeks)
Follow-up
(3 months)
Baseline End of
rehabilitation
(3 weeks)
Follow-up
(3 months)
Between group
difference of
change BL-3w
Between group
difference of
change BL-3 m
AQLQ Score 3.6 (3.1;4.8) 5.5 (4.4;6.4)*** 5.1 (3.8;5.9)*** 3.9 (3.1;4.6) 5.6 (4.4;6.3)*** 4.9 (3.5;6.2)* −.0 (−.7 to .8) −.5 (−1.6 to .3)
AQLQ Activity limitation 4.3 (3.5;5.1) 5.7 (4.4;6.3)** 5.0 (4.3;5.9)*** 4.4 (3.5;5.0) 5.9 (4.8;6.4)*** 5.0 (3.8;6.4)** .0 (−.7 to .7) −.1 (−.7 to .6)
AQLQ Symptoms 3.8 (3.3;4.9) 6.0 (4.9;6.5)*** 5.5 (4.0;6.0)** 3.7 (3.1;4.8) 5.4 (4.4;6.6)*** 5.5 (3.2;6.5)* −.2 (−1 to .7) −.5 (−1.9 to .4)
AQLQ Emotional function 3.4 (2.5;4.5) 5.0 (4.1;6.0)** 4.7 (3.7;6.4)*** 3.6 (2.7;4.6) 5.3 (3.8;6.6)*** 4.8 (2.8;6.0)** .0 (−.8 to .8) −.4 (−1.4 to .4)
AQLQ Environ-mental
stimuli
3.3 (2.1;4.0) 5.0 (3.2;6.2)** 4.3 (3.3;5.5)** 3.0 (2.6;4.5) 5.0 (4.6;5.9)*** 4.6 (3.0;5.7)** .0 (−1 to .8) .0 (−1 to .8)
SF − 36, PCS 40 (35;43) 40 (36;46) 42 (36;47) 50 (43;54) 46 (38;52) 51 (45;54) -3 (−10 to 3) −1 (−5 to 4)
SF − 36, MCS 44 (36;49) 41 (34;48) 44 (36;50) 51 (47;56) 48 (41;55) 58 (56;61) -3 (−12 to 5) 5 (−2 to 11)
Note: Data are given as median (quartiles) and median difference (confidence interval)
Abbreviations: AQLQ Asthma Quality of Life Questionnaire, SF-36 Short-form 36, PCS Physical component score, MCS mental summary score
*: p < 0.05; **: p < 0.01; ***: p < 0.001 tested with Wilcoxon test for paired samples (baseline vs. 3 week follow up and baseline vs. 3 months follow up)
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altitude was highly effective to render sustained improve-
ments in asthma control, quality of life and exercise cap-
acity directly after the rehabilitation and up to 3months.
We could show that exercise capacity assessed by the
6MWD and the STS improved significantly with our
comprehensive 3-week rehabilitation program and the
improvements were maintained up to 3 months follow-
up, potentially due to the continuation of daily exercise
according to the programs instruction in this highly mo-
tivated asthma collective. The improvement in exercise
capacity found in both our groups where slightly smaller
compared to other studies, assumedly because the re-
habilitation lasted 3 weeks compared to 12 weeks [7].
Another study with a 12-week rehabilitation program at
low altitude increased the exercise capacity in terms of
the VO2 max and the total treadmill time [27]. Whereas
the improvements in 6MWD were similar in the group
that trained at HA vs. LA, we found a better improve-
ment of the STS test in the HA vs. LA-group. This may
point towards a higher effect of training at HA on exer-
cise performance after return to LA. Such beneficial ef-
fects of altitude training have been previously described
for many athletes and HA-training has been incorpo-
rated in training plans due to its increase in hemoglobin
and thus oxygen transport [28]. Of interest, the additive
effect of HA rehabilitation on the STS were maintained
up to 3 months and might be at least partly explained by
a significant increase in hemoglobin in the HA-group.
The significant improvement of asthma specific quality
of life reflects an important effect of rehabilitation that
was achieved to a similar degree in the HA and LA group.
Also all sub scores of the AQLQ improved after the re-
habilitation and remained at this level at 3months follow
up in both groups without difference between groups.
The program was well tolerated by patients at both loca-
tions, expect one patient at altitude who suffered from
mild AMS (headache), no adverse events occurred. Intrin-
sically, it was not possible to blind investigators and pa-
tients to the intervention, and thus other factors than
altitude and rehabilitation such as being away from home
or factors concerning comfort might have played a role in
the outcomes. However, this would be the case with any
rehabilitation program all over the world. Among the par-
ticipants of our study, there were no current smokers.
Thus, our results may not be transferable to smoking
asthmatics. The current study population revealed a rela-
tively low and thus favorable daily PEF-variability and it
may well be that the effect of a rehabilitation program in-
cluding education and training would have been different,
potentially even better, in a more compromised asthma
collective. Despite these limitations, this study is of par-
ticular importance because of its robust design as a
randomize trial.
Conclusion
In the present randomized trial, we could show that a 3-
week comprehensive asthma rehabilitation program in-
cluding a clear action plan, peak flow diary, patient educa-
tion, respiratory exercises, force and endurance training is
highly effective in sustainably improving asthma control
in terms of the Co-primary outcome asthma-related qual-
ity of life (ACQ) and PEF-variability, but also exercise per-
formance and this positive effect was irrespective of the
altitude is the rehabilitation program was performed.
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